Shares of 10 Firms Soar on Friday

7. CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics rose for a fourth day on Friday, ending the day higher by 14.33 percent to finish at $49.72 apiece, as investors cheered its upgraded rating from an investment advisory firm.

On Friday, Evercore ISI upgraded CSP to “outperform” from “in line,” while significantly raising its price target by 65 percent to $99 from $60 previously, on expectations that its clinical trial programs, CTX320 and CTX310, would succeed by 10 percent and 5 percent, respectively, and contribute to the company’s growth.

CTX320 is in an ongoing clinical trial in patients with elevated lipoprotein(a), a cardiovascular risk factor that affects up to 20 percent of the global population. Dose escalation is ongoing, with an update expected in the first half of 2025.

Meanwhile, CTX310 is in an ongoing clinical trial targeting ANGPTL3 in patients with homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (SHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias. Dose escalation is ongoing, with an update expected in the first half of 2025.